Immune Globulin Subcutaenous (Human), 20%

Update Il y a 4 ans
Reference: NCT01412385

Woman and Man

Extract

The purpose of the study is to develop a 20% subcutaneous immunoglobulin treatment option for patients with primary immunodeficiency (PID) diseases.


Inclusion criteria

  • Primary Immunodeficiency diseases (PID)


Links